

Christoph B. Olivier

Personal Data

Name	Christoph Benedikt Olivier
Date of birth	May 7 th , 1982 (Villingen-Schwenningen, Germany)
Email	Christoph.Olivier@uniklinik-freiburg.de
Web	www.antithrombotic.org;
Linkedin	linkedin: christoph-b-olivier-7647b980



Curriculum Vitae

Education

2020	Postdoctoral Thesis (Habilitation); Faculty of Medicine, University of Freiburg.
2007 – 2010	Doctoral Thesis; Faculty of Medicine, University of Freiburg.
2010	Graduation (Medical Doctor) and license (Approbation); Faculty of Medicine, University of Freiburg; Landesärztekammer Baden-Württemberg.
2002 – 2010	Medical School, University of Freiburg.

Board Certifications

2021	Internal Medicine and Cardiology (Landesärztekammer Baden-Württemberg).
2016	Internal Medicine (Landesärztekammer Baden-Württemberg).

Current Positions

Since 2024	Associate Professor, Faculty of Medicine, University of Freiburg.
Since 2024	Head of Clinical Research, Department of Cardiology and Angiology, University Heart Center Freiburg Bad Krozingen (Chair: Prof. Dr. Westermann).
Since 2023	Director, Cardiovascular Clinical Research Center (CCRC), Department of Cardiology and Angiology, University Heart Center Freiburg Bad Krozingen.
Since 2020	Attending Physician, Department of Cardiology and Angiology, University Heart Center Freiburg Bad Krozingen.

Professional Activities

2025 - 2027	Chair, AG19 "Kardiovaskuläre Hämostase und antithrombotische Therapie", DGK.
2015 - 2025	Co-Chair, AG19 "Kardiovaskuläre Hämostase und antithrombotische Therapie", DGK
2024 - 2028	Nucleus Member, Working Group on Thrombosis, European Society of Cardiology (ESC)
2019 - Present	Nucleus Member, AG19, German Cardiac Society (DGK) 2019 – Present

Personal Awards

2019	Young Cardiologist grant; Scientific Sessions 2019, European Society of Cardiology.
2018	Young Investigator Award – Coronary Heart Disease; Annual Meeting of the German Cardiac Society 2018.
2017	Stanford Cardiovascular Institute grant, Stanford University.
2012	Young Cardiologist grant; Scientific Sessions 2012, European Society of Cardiology.
2010	DFG grant fellowship “Nachwuchsakademie Klinische Studien”.
2008	Grant “Prof. Dr. Dr. Freifrau von Kleist Stiftung” for participation at the Scientific Session 2008 of the American Heart Association.

Publication list. Selection.

1. Zeymer U, Koolaji S, Araiza-Garaygordobil D, Clemmensen P, Gramegna M, Krychtiuk KA, **Olivier CB**, Rubboli A, Schrage B, Vandenbriele C, Huber K, Gorog DA. Injectable antiplatelet therapies in acute coronary syndromes: Current status and Emerging Therapies. A position paper of the Task Force of Antithrombotic therapy of the ACVC. Eur Heart J Acute Cardiovasc Care. 2026 Aug 21:zuag113. doi: 10.1093/ehjacc/zuag113. Epub ahead of print. PMID: 42626985. (JCR 2025: IF 45.3)
2. Horstmann H, Anto Michel N, Losert C, Abogunloko T, Peikert A, Hansen S, Hazard D, Gissler MC, Marchini T, Eberhardt N, Amend A, Bacmeister L, Siegel PM, Ley K, Libby P, Giannarelli C, Hilgendorf I, von Zur Mühlen C, Bugger H, **Olivier CB**, Sheng X, Pfeil K, Winkels H, Gerhard T, Oelen R, Franke L, van der Harst P, van der Wijst MGP, Kleber ME, Scharnagl H, Dressel A, Pekayvaz K, Stark K, Heinig M, Westermann D, März W, Zirlik A, Wolf D. Immunological risk identified by single-cell multi-omics and cardiovascular outcomes. Eur Heart J. 2026 Aug 14:ehag553. doi: 10.1093/eurheartj/ehag553. Epub ahead of print. PMID: 42596600. (JCR 2025: IF 45.3)
3. Gjermani D, Geisler T, Müller K.A.L, Trenk D, Petzold T, Mehilli J, Rauch B, Rudolph T. K. Waßmann S., Hochholzer W & **Olivier CB**. Umstellung antithrombozytärer Therapien: Interaktionen und praktische Durchführung– DGK-Empfehlung. Kardiologie (2026). <https://doi.org/10.1007/s12181-026-00821-8> (JCR 2026: IF 1.15)
4. Gjermani D, Szabó S, Anfang V, Vetter H, Juelch C, Rademacher S, Li T, Leggewie S, Hesselbarth D, Duerschmied D, Trenk D, Westermann D, **Olivier CB**. “CYP2C19 Polymorphism and Platelet Aggregation-Associated Risks in Atrial Fibrillation Patients Undergoing PCI,” Clinical and Translational Science, no. 6 (2026): e70598, <https://doi.org/10.1111/cts.70598>. (JCR 2024: IF 2.8)

5. Rosenfield K, Klok F.A, Piazza G, Sharp A.S.P, Ní Áinle F, Jaff M.R, Barco S, Goldhaber S.Z, Kucher N, Lang I.M, Schmidtman I, Sterling K.M, Araszkiwicz A, Arora V, Cires-Drouet R, Coghlan J, Hobohm L., Ito W., Jacobson K, Kaiser C, Kopec G, Marx K, McElwee S, Meneveau N, Monteleone P, Montero-Cabezas J.M., **Olivier CB**, Park J, Roik M, Sakhuja R, Tego A, Theurl M, Visveswaran G, Vos J.A, Young M.N, Asch F.M., and Konstantinides S.V, for the HI-PEITHO Investigators. Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism. NEJM. 2026 Mar 28. DOI: 10.1056/NEJMoa2516567. (JCR 2024: IF 78.5)
6. Hesselbarth D, D’Orazio M, Ciccarone G, Gjermeni D, Jülch C, Breitbart P, Ruile P, Hein M, Wessinger M, Maslarska M, Rilinger J, Schlett C, Bamberg F, Kaier K, Duerschmied D, Pottgiesser T, Mühlen Cvz, Westermann D, **Olivier CB**, Associations of Biomarkers with Hypoattenuated Leaflet Thickening after Transcatheter Aortic Valve Replacement, Research and Practice in Thrombosis and Haemostasis (2026), doi: <https://doi.org/10.1016/j.rpth.2025.103341>. (JRC 2024: IF 3,4)
7. Hesselbarth D, D’Orazio M, Ciccarone G, Gjermeni D, Jülch C, Wessinger M, Maslarska M, Rilinger J, Hilgendorf I, Wolf D, Kaier K, Duerschmied D, Pottgiesser T, von Zur Mühlen C, Westermann D, **Olivier CB**. Fibrin clot strength is associated with increased risk of major adverse cardiac events after TAVR. Clin Res Cardiol. 2025 Oct 6. doi: 10.1007/s00392-025-02749-7. Epub ahead of print. PMID: 41051422. (JRC 2024: IF 3,7)
8. Gjermeni D, Vetter H, Szabó S, Anfang V, Juelch C, Leggewie S, Hesselbarth D, Jäckel M, Duerschmied D, Trenk D, Westermann D, **Olivier CB**. Platelet Reactivity and Fibrin Clot-Strength as assessed by TEG in Patients with Atrial Fibrillation undergoing Percutaneous Coronary Intervention. J Cardiovasc Transl Res. 2025 Aug 27. doi: 10.1007/s12265-025-10673-4. Epub ahead of print. PMID: 40866669.
9. Zeymer U, **Olivier CB**, Duerschmied D. Aspirin in Dual Antiplatelet Therapy After PCI: One Duration Does Not Fit All. Circulation: Cardiovascular Interventions. 2025 Jul. (JCR 2023: IF 35.6)
10. Dominik Felbel, Merten Prüser, Constanze Schmidt, Björn Schreiweis, Nicolai Spicher, Wolfgang Rottbauer, Julian Varghese, Andreas Zietzer, Stefan Störk, Christoph Dieterich, Dagmar Krefting, Eimo Martens, Martin Sedlmayr, Dario Bongiovanni, **Christoph B Olivier**, Hendrik Lapp, Hannes Schmidt, Julius L Katzmann, Felix Nensa, Norbert Frey, Gudrun S Ulrich-Merzenich, Carina A Peter, Peter Heuschmann, Udo Bavendiek, Sven Zenker, the ACRIBiS Study Group , The “Advancing Cardiovascular Risk Identification with Structured Clinical Documentation and Biosignal Derived Phenotypes Synthesis” (ACRIBiS) Project – Conceptual Design, Project Planning, and First Implementation Experiences, European Heart Journal - Digital Health, 2025; ztaf075, <https://doi.org/10.1093/ehjdh/ztaf075> (JCR 2024: IF 4.4)